N-Naphthalen-1-ylmethyl-oxalamic acid | 81682-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-Naphthalen-1-ylmethyl-oxalamic acid
• 英文别名: Oxamic Acid/Ester, 17；2-(naphthalen-1-ylmethylamino)-2-oxoacetic acid
• CAS: 81682-61-3
• 化学式: C₁₃H₁₁NO₃
• 分子量: 229.235
• InChiKey: BLGHGFMMYLUFQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-Naphthalen-1-ylmethyl-oxalamic acid 在 戴斯-马丁氧化剂 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 苯甲醚 为溶剂， 反应 3.25h， 生成 (S)-3-{(S)-3-Methyl-2-[(naphthalen-1-ylmethyl)-aminooxalyl]-amino}-butyrylamino)-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid
  参考文献：
  名称：

  Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

  摘要：

  Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.106
• 作为产物：
  描述：

  1-萘甲基胺 在 lithium hydroxide 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-Naphthalen-1-ylmethyl-oxalamic acid
  参考文献：
  名称：

  Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

  摘要：

  Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.106

文献信息

• C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020042376A1

  公开（公告）日：2002-04-11

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及在治疗患有炎症性、自身免疫和神经退行性疾病的患者中使用这些组合物，用于预防缺血性损伤，并用于保存即将进行移植手术的器官。
• C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020028774A1

  公开（公告）日：2002-03-07

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新颖的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及将这些组合物用于治疗患有炎症、自身免疫和神经退行性疾病的患者，预防缺血性损伤，并保护将要进行移植手术的器官。
• [EN] C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES<br/>[FR] OXAMYL DIPEPTIDES A TERMINAL C MODIFIE EN TANT QU'INHIBITEURS DE LA FAMILLE ICE/ced-3 DES PROTEASES DE CYSTEINE
  申请人：IDUN PHARMACEUTICALS INC

  公开号：WO2000001666A1

  公开（公告）日：2000-01-13

  This invention is directed to novel oxamyl depeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl depeptide ICE/ced-3家族抑制剂化合物。本发明还涉及含有这些化合物的制药组合物，以及在治疗患有炎症、自身免疫和神经退行性疾病的患者，预防缺血性损伤以及保护即将进行移植手术的器官中使用这些组合物的方法。
• Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
  申请人：Idun Pharmaceuticals, Inc.

  公开号：EP1754475A1

  公开（公告）日：2007-02-21

  The present invention relates to the use of compounds for formula (I), wherein R1, A, B and R2 are defined herein, for the manufacture of a medicament for the treatment of an infectious disease or an inflammatory condition or for prolonging organ viability for use in transplantation.

  本发明涉及式(I)化合物的用途，其中 R1、A、B 和 R2 在本文中定义，用于制造治疗传染性疾病或炎症的药物，或用于延长移植手术中器官的存活时间。
• C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
  申请人：Idun Pharmaceuticals, Inc.

  公开号：EP1091930A1

  公开（公告）日：2001-04-18